Clinical Trials
28 trialsPOPLIN
Regeneron Pharmaceuticals
ADES
Peking University Cancer Hospital & Institute
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
Peking University People's Hospital
STAT-CAT
Brigham and Women's Hospital
B-BIT
Seoul St. Mary's Hospital
Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP
The First Affiliated Hospital with Nanjing Medical University
E-STOP2
Hospital Universitari Vall d'Hebron Research Institute
Skin Subs vs Secondary Intention
Baylor Research Institute
SHAPE-ENDO
Hospital Universitari de Bellvitge
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Swiss Cancer Institute
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Blue Earth Diagnostics
A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui Tongbian Capsules Combined With Pancreatin Enteric-coated Capsules on Pancreatic Exocrine Function in Patients After Curative Resection for Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
STARGATE
University Hospital, Essen
PRECISE AM
Nanfang Hospital, Southern Medical University
DOSABEMA
Poitiers University Hospital
A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
Huazhong University of Science and Technology
CervALONE
International Agency for Research on Cancer
Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing
LanZhou University
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
The Affiliated Hospital of Qingdao University
REVIVE
AstraZeneca
NG-ST
Vastra Gotaland Region
BLOOD-dose
Rigshospitalet, Denmark
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Weill Medical College of Cornell University
CYTALUX Dose Extension Study
On Target Laboratories, LLC
AmiCARE
Shanghai Pulmonary Hospital, Shanghai, China
REPROG-RCT
Yonsei University
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University